Approved May 2001
FINEVIN, a twice-daily topical azelaic acid cream, has been approved for the treatment of mild to moderate acne vulgaris. It is the second azelaic acid product available in the United States and represents a cost-effective and well-tolerated acne treatment.
Acne affects more than 17 million people in the United States and is the most common skin condition treated by physicians. Acne vulgaris, or common acne, is a disease that affects the sebaceous glands of the skin, resulting in inflammatory and/or non-inflammatory lesions.
Clinical studies with FINEVIN in both the United States and Europe have shown the drug to be effective in treating mild to moderate acne. FINEVIN demonstrated antimicrobial activity against Propionibacterium acnes and Staphylococcus epidermis, normalized the follicular hyperkeratosis associated with acne, and produced anti-inflammatory effects. In the majority of patients, improvements in acne were seen within four weeks of beginning treatment.
Adverse events associated with the use of azelaic acid cream may include (but are not limited to) the following:
The exact mechanism of action of FINEVIN (azelaic acid cream) is unknown. The antimicrobial action of azelaic acid may be attributed to inhibition of microbial cellular protein synthesis.
For additional information on FINEVIN, please visit Berlex.
The Finevin drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.